Administration of Ang1–7, rhACE2, and ACE2 activator drugs (XNT and DIZE) have local, tissue-level hepatoprotective effects in rodents and are promising in other organ systems, but their systemic effects in human liver disease are unknown and further animal studies are required to confirm their efficacy and safety. This evidence concerns the gene ACE2 and liver disorder.